The complexities of treatment pathways and patient comorbidities has necessitated improved diagnostics and therapeutics to enable optimised cardiovascular care at all stages of cancer therapy. Therapeutic breakthroughs in the past few decades have significantly increased the life expectancy of people with cancer . As a result, the role that cardiovascular disease (CVD) plays in this patient cohort is now better understood. This is a rapidly evolving area of medicine and the development of new consensus guidelines, cardio-oncology societies, and both scientific and clinical research make it an exciting and important field to be involved in.A multidisciplinary management approach is necessary given the complexity of the patients, the treatments involved and the highly specialised nature of their care.Identifying cardiovascular issues early and intervening promptly enables us to optimise treatment plans and improve patient mortality and morbidity.Understanding the interactions between different cancer treatments and cardiovascular disease is essential to ensure patient safety.Cardiovascular issues can occur at all stages of cancer treatment.Journal of Pharmaceutical Health Services Research.International Journal of Pharmacy Practice.Antimicrobial resistance and stewardship.Conclusion: In Italy, the rates of thrombotic thrombocytopenia following COVID-19 immunisation with viral vector vaccines are in line with those reported in other Countries. Women aged 30 to 49 years showed the highest reporting rates. Seventy-seven cases were classifiable as BCG levels 1, 2, and 3 (definite, probable and possible cases, respectively) with an overall reporting rate at about 1 case per approximately 200,000 doses administered. Furthermore, 3 reports were excluded because of a hereditary thrombophilia or a previous history of other thrombotic episodes. 27 reports were defined as 'not case' (level 5, Brighton) on the basis of clinical examination or investigation, or because of the presence of heparin as a concomitant drug. A total of 134 reports after vaccination with adenoviral vaccines were identified according to the inclusion criteria, of which 107 cases were defined as thrombotic thrombocytopenia (95 following ChAdOx1-S and 12 after Ad26.COV2-S). Disagreement were resolved by plenary discussion. The selected ICRSs were submitted to the independent evaluation of three pharmacovigilance experts who blindly classified into 5 levels of diagnostic certainty, according to the definition provided by the Brighton Collaboration Group ( BCG)3. All cases of thrombotic and thromboembolic events reporting thrombocytopenia in the narrative description of the report were also reviewed. Objective: To present a comprehensive assessment of thrombotic and thromboembolic events associated with thrombocytopenia following COVID-19 immunisation with viral vector vaccines recorded in the Italian National Pharmacovigilance Network database Methods: We selected all ICSRs reported from 27 December 2020 to 26 December 2021 containing Preferred Terms (PT) related to platelet count reduction associated with PT related to thrombotic and thromboembolic events (clinical symptoms and/or diagnostic tests). During the first months of the vaccination campaign, a signal of rare events of thrombosis associated with thrombocytopenia2, particularly in young women, was detected by health authorities associated with the viral vector vaccines ChAdOx1S S Ad26.COV2-S. ABSTRACT Introduction: During large-scale vaccination campaign against COVID-19, the Italian Medicines Agency (AIFA) in collaboration with the Regional Centres of Pharmacovigilance have carried out a closely monitoring of Individual Case Safety Reports (ICSRs) about Adverse Event Following Immunisation (AEFIs) related to COVID19 vaccines and have assured a constant communication through public monthly reports1.

Thromboembolic phenomena definition